alternatives to glp-1 agonists Costs Explained: Managing Coverage Challenges switching glp 1 agonists GLP-1-based

This approach doesnt just tackle obesity or diabetes in isolation

Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: the SURMOUNT-4 Randomized Clinical Trial

Most of the following reports caught my eye on Medscape.com, which has done a good job tracking developments with this class of drugs

Ideal Candidates for Direct Meds Adults with a BMI of 27+ with a weight-related health condition, or BMI of 30+ Patients who cannot afford or access brand-name GLP-1 medications through insurance People in states where Direct Meds USA operates who prefer a fully remote pharmacy experience Patients who have been screened and recommended for semaglutide or tirzepatide by a prior provider Individuals comfortable managing their care through a digital patient portal Who Should Avoid Direct Meds or Proceed with Caution Pregnant or breastfeeding women, GLP-1 medications are contraindicated Anyone under 18 years of age Patients with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2) Patients with severe pancreatitis history or active pancreatic disease People in states not currently served by Direct Meds of Florida This qualification overview is for general guidance only

moreover, most were not analysed for outcomes based on presence of HF at enrolment